Evidence map›Paper›PMID 41395719›Full record

ReviewMedicinal chemistry (Shariqah (United Arab Emirates))2025

Pyridazinone: Current Progress in Synthesis of its Derivatives and Biological Activity.

Shilpi Pathak, Vishnu Sharma, Neetu Agrawal, Sangeeta Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medicinal chemistry (Shariqah (United Arab Emirates)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shilpi PathakInstitute of Pharmaceutical Research, GLA University, Uttar Pradesh, Mathura, 281406, India.
Vishnu SharmaInstitute of Pharmaceutical Research, GLA University, Uttar Pradesh, Mathura, 281406, India.
Neetu AgrawalInstitute of Pharmaceutical Research, GLA University, Uttar Pradesh, Mathura, 281406, India.
Sangeeta SharmaV.A.T.S Healthcare Products, Sonepat, Haryana, 131001, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyridazinone, a six-membered heterocyclic molecule, has emerged as an important pharmacophore in drug discovery due to its diverse range of biological actions. This adaptable scaffold has shown tremendous promise in the development of therapeutic medicines for a variety of pharmacological conditions, including anti-inflammatory, anti-cancer, anti-microbial, cardiovascular, and central nervous system illnesses. Pyridazinone derivatives are useful in medicinal chemistry due to their propensity to interact with a wide range of biological targets. This review offers a comprehensive overview of Pyridazinone-based compounds, focusing on their chemical structure, mechanism of action, structure-activity relationship (SAR), and therapeutic uses. Current trends in Pyridazinone research and its potential as a lead chemical for new medication development are also reviewed. Pyridazinone broad range of activity and adaptability highlight its importance in developing pharmacotherapy.

Indexed as

PyridazinesAnimalsAnti-Infective AgentsAntineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipAnti-Infective AgentsAntineoplastic AgentsPyridazinesheterocyclic compoundpharmacological activitypharmacophorePyridazinonestructures.synthesis

Identifiers

PMID41395719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.